Brk (PTK6) is a nonreceptor protein tyrosine kinase, which is expressed in over 60% of breast carcinoma tissue samples and breast tumour cell lines, but not normal mammary tissue or benign lesions. Since experimental Brk expression in nontransformed mammary epithelial cells enhances their mitogenic response to epidermal growth factor, it was important to determine the role Brk plays in the proliferation of breast carcinoma cells and validate it as a therapeutic target. We have used RNA interference to efficiently and specifically downregulate Brk protein levels in breast carcinoma cells, and determined that this results in a significant suppression of their proliferation. Additionally, through the expression of a kinase-inactive mutant, we have determined that Brk can mediate promotion of proliferation via a kinaseindependent mechanism, potentially functioning as an 'adapter'. These data identify Brk as a novel target for antiproliferative therapy in the majority of breast cancers, and illustrate the power of RNA interference for rapidly validating candidate therapeutic targets.
Introduction
Tyrosine kinases are regulators of cellular signalling and deregulation of their function is common in the development of tumours. We have previously identified a nonreceptor tyrosine kinase Brk (PTK6) (Mitchell et al., 1994) , which is expressed in a majority of human breast cancer tissue samples and tumour cell lines, but not normal breast tissue or benign mammary lesions (Barker et al., 1997) . Brk expression in normal adult tissues is restricted (Lee et al., 1998; Llor et al., 1999) , and has been characterized in the gastro-intestinal tract where it is present in normal differentiating epithelial cells. Brk expression is also elevated in colon tumours (Llor et al., 1999) . In support of the hypothesis that deregulated Brk expression is mechanistically important in breast tumour development, we have found that experimental expression of Brk at pathologically relevant levels in immortalized mammary cells leads to their sensitization to the mitogenic effects of epidermal growth factor (EGF), and enhanced anchorage-independent growth (Kamalati et al., 1996) .
Brk associates with two members of the EGF/erbB receptor family, EGFr and erbB3 (Kamalati et al., 1996 (Kamalati et al., , 2000 , and these interactions may be necessary for Brk's potentiation of EGF-mediated mitogenic signalling. Brk expression enhances EGF-induced phosphoinositide 3-kinase recruitment to erbB3, and subsequent phosphorylation of Akt (Kamalati et al., 2000) . Activation of EGF receptor family tyrosine kinases is strongly implicated in the progression of many human cancers, including breast tumours (reviewed in Kim and Muller, 1999) . ErbB3 is overexpressed in a subset of human breast tumours, while erbB2 overexpression occurs in a significant number of breast cancers and patient survival has been inversely correlated to erbB2 expression levels (reviewed in Olayioye et al., 2000) . Since there is also mounting evidence that phosphoinositide 3-kinase regulation is important in the development of breast tumours (reviewed in Fry, 2001) , Brk has an intimate involvement in pathologically relevant signalling pathways.
In order to examine potential functions of Brk in breast tumour development, we suppressed its expression using RNA interference (RNAi) in cultured human breast carcinoma cells. RNAi is the sequence-specific degradation of mRNAs initiated by double-stranded (ds)RNA of homologous sequence, and has been found to operate in a variety of organisms (reviewed in Hutvagner and Zamore, 2002) . Mammalian somatic cells manifest sequence-independent responses to dsRNA above B30 base pairs (bp) in length. The use of RNAi for gene function analysis in mammalian cells therefore requires the introduction of short (o30 bp) small interfering dsRNAs (siRNAs) (Caplen et al., 2001; Elbashir et al., 2001) .
We transfected T-47D breast carcinoma cells with Brk-targeting or control siRNA duplexes twice at 24 h intervals, and obtained comparable results with siRNAs targeting two different regions of the Brk mRNA. We consistently found that transfection of the Brk-targeting siRNAs resulted in the efficient suppression of Brk protein when assessed by Western blotting, using cytokeratin 18 levels as an internal control (Figure 1) . 0 -CGAACACUUGAUGGUGUCCTT-3 0 , BrkB reversed). siR-NA duplex (3 ml 20mm) was transfected into 10 5 cells using Oligofectamine (Invitrogen). Transfection efficiencies of over 90% were obtained (determined with a fluorescently labelled oligonucleotide, data not shown). Proteins were detected with HRP-conjugated secondary antibodies (DAKO Ltd.) and chemiluminescent substrate (Pierce) Figure 1 ). Average Brk expression levels were estimated by densitometry, and the extent of RNAi-mediated Brk suppression calculated. .0003, n ¼ 6). For growth curves, 10 5 cells were seeded at day 0 in 10% serum. Monolayers were washed and medium replaced for siRNA transfections (see Figure 1) , carried out on days 1 and 2. Fresh medium was added on day 4. Cell numbers were determined daily by a haemocytometer. For BrdU incorporation, cells were transfected with siRNA as described above. At 24 h after the second transfection, cells were incubated with 10 mm BrdU (Sigma-Aldrich Co. Ltd) for 2 h, harvested, fixed in 4% paraformaldehyde, then 70% methanol, and air-dried onto poly-llysine-coated slides. Cells were incubated in 2 m HCL, washed in water, and incubated in pepsin (0.2 mg/ml in 10 mm HCl). After blocking for 30 min in 1% BSA/0.5% Tween-20 in TBS, cells were incubated with anti-BrdU-FITC (10 mg/ml in blocking solution) (Dako Ltd), washed in TBS, and counterstained with 0.25 mg/ml DAPI (Sigma-Aldrich Co. Ltd). BrdU-incorporating cells identified by fluorescence microscopy were expressed as a percentage of DAPI-stained cells. Data were statistically analysed using Student's t-test for unpaired values, Po0.05 was considered significant. Results are expressed as means7standard deviation c Role of Brk in breast carcinoma cell proliferation AJ Harvey and MR Crompton
We assessed the effects of suppressing Brk expression by determining the growth rates of T-47D cell populations transfected with either control or Brk-targeting siRNAs. The RNAi-mediated decrease in Brk protein levels was accompanied by a decline in the rate of population growth approximately 48 h post second transfection, when compared to cells transfected with control siRNAs (Figure 2a) . In the absence of significant levels of apoptosis under any of the experimental conditions (determined by measurement of a sub-G0/G1 peak of DNA content by flow cytometry, detection of condensed chromatin by DAPI staining, or detection of activated caspases, data not shown), this demonstrated that suppression of Brk expression had reduced the rate of cell proliferation.
In order to dissect further the role of Brk in breast carcinoma cell proliferation, we determined the rate of DNA synthesis of cells after transfection with Brktargeting or control siRNAs. We observed a statistically significant reduction in DNA synthesis as measured by BrdU incorporation 24 h after Brk-targeting, as compared to controls, with the highest P-value obtained being less than 0.0048 (Figure 2b ). This indicated that cells with suppressed Brk levels either entered or progressed through S phase at a slower rate.
The design of selective or specific protein kinase inhibitors in drug development has attracted much attention. As our previous studies had shown that Brkkinase activity is required for the transformation of NIH-3T3 murine fibroblasts to anchorage-independent proliferation (Kamalati et al., 1996) , we investigated the importance of Brk-kinase activity in promoting breast carcinoma cell proliferation. We transfected T-47D cells with either an empty expression vector (control), or a construct directing the expression of a kinase-inactive mutant Brk (Kamalati et al., 1996) , epitope tagged to differentiate it from endogenously expressed Brk (Figure 3a) . Notably, the expression of kinase-inactive Brk enhanced the proliferation of these cells relative to the control cells (Figure 3b) , indicating a previously unexpected kinase-independent role for Brk in regulating the proliferation of breast cancer cells.
Until recently, it had been extremely difficult to directly analyse the functions of genes in human cells. Experiments based on the overexpression of molecules, or mutants thereof with predicted dominant functional effects, have often been interpreted as providing indirect readouts of the activity of endogenously expressed molecules in cultured human cells. Such studies suffer potential artefacts associated with the likelihood that overexpressed proteins will make inappropriate associations due to their high concentrations, and the possibility that mutants with predicted 'dominantnegative' functions may have unanticipated properties. The latter is highlighted by our finding that a kinaseinactive Brk mutant has proliferation-promoting activity in breast carcinoma cells, and is thus unlikely to interfere with all of the functions of endogenously expressed Brk (in which case it would have been predicted to inhibit proliferation). The use of RNAi circumvents these problems by allowing the direct transfected cells were plated in medium containing 10% serum and 400 mg/ml G418, and cell numbers determined by a haemocytometer (fresh medium added every 2-3 days). P-values, determined by Student's t-test, are 0.0054 (day 7) and 0.0017 (day 9) suppression of accumulation of endogenously expressed molecules, and has allowed us for the first time to validate Brk as a therapeutic target in human breast tumour cells. It might now be prudent to employ RNAi to confirm the functional assignments made previously for other human genes using approaches such as the introduction of dominant-negative mutants. Recent advances in the design of siRNA expression vectors for use in human cells will allow stable suppression (reviewed in Tuschl, 2002; Zeng et al., 2002) , and other somatic cell constitutive gene-targeting approaches have also been successfully employed in gene function analyses. However, the transfection of in vitro synthesized siRNAs is likely to become an important and widely used methodology, and is unlikely to be superseded entirely by the recent vector-based approaches, due to its rapidity, reliability, and ease of application in the study of molecules promoting proliferation and/or viability. The use of siRNA-encoding vectors to study this latter class of molecules, of which Brk is an example in carcinoma cells, will be facilitated by future developments allowing selection for transfected cells, before the establishment of a compromised phenotype by inducible siRNA expression. Until then, siRNA transfection will remain the most straightforward approach.
There is currently a pressing need to develop novel strategies for the treatment of breast tumours; for example this disease is now reported to be the commonest cancer in the United Kingdom. Therapies designed to take advantage of tumour-specific molecular alterations hold the promise of effective intervention accompanied by minimized unwanted side effects for the patient, and we propose that Brk represents a promising novel therapeutic target. Through employing RNAi, we have unambiguously assigned to Brk a role in promoting the proliferation of breast carcinoma cells, and interfering pharmacologically with its function would therefore be predicted to slow or arrest the development of breast tumours. The degree to which cell proliferation would be inhibited is currently difficult to predict, since we have never achieved the suppression of Brk expression to undetectable levels. It thus remains possible that the majority of cells in an RNAi-targeted population retain low but functionally relevant levels of Brk, and drug targeting may achieve larger inhibitory effects than siRNAs. Whether therapies directed at Brk could be of additional use in combination with other agents, for example to enhance the apoptosis of tumour cells, will be the subject of future investigation.
The pattern of Brk expression suggests that targeted therapies would be unlikely to be associated with wideranging unwanted side effects. While it is expressed in breast tumour cells, but not normal mammary tissue (Barker et al., 1997) , its expression (and that of its murine counterpart Sik) in normal tissues is confined primarily to epithelial cells of the skin and alimentary canal. Further, those normal cells that do express it are outside the proliferative compartments of the tissues (Vasioukhin et al., 1995; Llor et al., 1999) indicating that interfering with proliferative signalling by Brk would provide a highly specific therapeutic intervention. In order to design drugs with such specificity, further research into signalling pathways employed by Brk in carcinoma and normal cells is required, in order to identify those functions of Brk that account for its selective proliferation-promoting role in tumour cells. Indeed, the 'simple' hypothesis that selectively inhibiting its kinase activity will be a suitable strategy is contradicted by our finding that Brk has a kinase-independent function in promoting carcinoma cell proliferation, and siRNA delivery is presently not sufficiently developed for RNAi itself to represent a viable therapeutic approach for solid, possibly disseminated, tumours. Inhibiting specific Brk-mediated protein-protein interactions may provide therapeutic opportunities, by interfering with either Brk conformational activation (Qui and Miller, 2002) or downstream signalling. Brk (and/or the murine counterpart Sik) have been found in complexes with the EGFr (Kamalati et al., 1996) , GTPase activating protein-associated p65 (Vasioukhin and Tyner, 1997) , the putative adapter protein Bks (Mitchell et al., 2000) , the RNA-binding protein Sam68 (Derry et al., 2000) , and the EGFr family member erbB3/HER3 (Kamalati et al., 2000) . The latter two interactions have been shown to occur in the absence of Brk/Sik-kinase activity, and are thus candidates for mediating kinase-independent proliferative signalling in which Brk has a 'signalling adapter'-like function.
By comparison with other common molecular aberrations that have been discovered in breast tumours, for example mutation of the gene encoding p53 (B20% of cases) or overexpression of c-erb-B-2 (25-30% of cases) (reviewed in Gasco et al., 2002; Hayes and Thor, 2002) , Brk overexpression is notable. Approximately 60% of breast cancers express Brk protein, and novel therapies targeting this molecule could therefore benefit a large number of patients.
